Literature DB >> 21325372

Epigenetics of thyroid cancer and novel therapeutic targets.

Diego Russo1, Giuseppe Damante, Efisio Puxeddu, Cosimo Durante, Sebastiano Filetti.   

Abstract

An increasing body of evidence suggests that epigenetic changes (DNA methylation, remodeling and post-translational modification of chromatin) play important roles in thyroid tumorigenesis, as a result of their effects on tumor-cell differentiation and proliferation. Epigenetic silencing of various thyroid-specific genes has been detected in thyroid tumors. These changes can diminish the tumor's ability to concentrate radioiodine, which dramatically reduces treatment options. Epigenetic changes in tumor-promoting and tumor-suppressor genes also contribute to the dysregulation of thyrocyte growth and other aspects of tumorigenesis, such as apoptosis, motility and invasiveness. We provide a brief overview of the mechanisms underlying epigenetic regulation of gene expression and the current methods used to investigate it. This is followed by a review of the principal epigenetic alterations detected in thyroid cancer cells, epigenetic strategies for treating thyroid cancers and data from preclinical and clinical studies (some still underway) on the use in this setting of demethylating agents and histone deacetylase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325372     DOI: 10.1530/JME-10-0150

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  38 in total

1.  Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Authors:  F Rosignolo; V Maggisano; M Sponziello; M Celano; C R T Di Gioia; M D'Agostino; L Giacomelli; A Verrienti; M Dima; V Pecce; C Durante
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

2.  5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.

Authors:  Geneviève Dom; Vanessa Chico Galdo; Maxime Tarabichi; Gil Tomás; Aline Hébrant; Guy Andry; Viviane De Martelar; Frédérick Libert; Emmanuelle Leteurtre; Jacques E Dumont; Carine Maenhaut; Wilma C G van Staveren
Journal:  Thyroid       Date:  2013-03       Impact factor: 6.568

3.  Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.

Authors:  Federica Baldan; Elisa Lavarone; Carla Di Loreto; Sebastiano Filetti; Diego Russo; Giuseppe Damante; Cinzia Puppin
Journal:  Mol Biol Rep       Date:  2014-05-21       Impact factor: 2.316

4.  Detection of global hypermethylation in well-differentiated thyroid neoplasms by immunohistochemical (5-methylcytidine) analysis.

Authors:  S Keelawat; P S Thorner; S Shuangshoti; A Bychkov; N Kitkumthorn; P Rattanatanyong; W Boonyayothin; U Poumsuk; P Ruangvejvorachai; A Mutirangura
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

5.  Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.

Authors:  Mosin S Khan; Arshad A Pandith; Shariq R Masoodi; Khursheed A Wani; Mahboob Ul Hussain; Syed Mudassar
Journal:  Endocrine       Date:  2014-06-14       Impact factor: 3.633

6.  Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.

Authors:  Mariavittoria Dima; Valeria Pecce; Mauro Biffoni; Cira Rosaria Tiziana Di Gioia; Giovanni Tallini; Marco Biffoni; Francesca Rosignolo; Antonella Verrienti; Marialuisa Sponziello; Giuseppe Damante; Diego Russo; Cosimo Durante
Journal:  Endocrine       Date:  2015-09-14       Impact factor: 3.633

Review 7.  Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.

Authors:  Stefania Bulotta; Marilena Celano; Giuseppe Costante; Diego Russo
Journal:  Endocrine       Date:  2015-12-21       Impact factor: 3.633

8.  Somatic amplifications and deletions in genome of papillary thyroid carcinomas.

Authors:  Nadia Passon; Elisa Bregant; Marialuisa Sponziello; Maria Dima; Francesca Rosignolo; Cosimo Durante; Marilena Celano; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

9.  PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.

Authors:  Marialuisa Sponziello; Antonella Verrienti; Francesca Rosignolo; Roberta Francesca De Rose; Valeria Pecce; Valentina Maggisano; Cosimo Durante; Stefania Bulotta; Giuseppe Damante; Laura Giacomelli; Cira Rosaria Tiziana Di Gioia; Sebastiano Filetti; Diego Russo; Marilena Celano
Journal:  Endocrine       Date:  2015-04-03       Impact factor: 3.633

10.  Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Ioanna Delladetsima; Ioanna Giannopoulou; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2013-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.